SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Reddit, Inc. operates an entertainment, social networking, and news website where registered community members can submit content. The firm provides online news services where users can select and rank web content. It also offers a personalized filter on the day's story, using previous votes to determine what new things the user might like to read. The company was founded by Steven Ladd Huffman and Alexis Ohanian on June 23, 2005 and is headquartered in San Francisco, CA.

Reddit Inc. - Ordinary Shares - Class A

Reddit Inc

Reddit is trending following a blowout earnings report that shattered revenue and earnings expectations, driven by rapid ad monetization and AI-related growth. While the stock saw significant pre-market gains, the community remains divided between long-term bulls highlighting strong fundamental execution and skeptics who are bracing for a potential post-earnings pullback based on historical volatility.

TMC the metals co., Inc. is a deep-sea minerals exploration company focused on the collection and processing of polymetallic nodules found on the seafloor in international waters of the Clarion Clipperton Zone in the Pacific Ocean (CCZ). These nodules contain high grades of four metals (nickel, copper, cobalt, manganese) which can be used as (i) feedstock for battery cathode precursors (nickel, cobalt and manganese sulfates, or intermediate nickel-copper-cobalt matte) for electric vehicles (EV) and renewable energy storage markets, (ii) copper cathode for EV wiring, energy transmission and other applications and (iii) manganese silicate for manganese alloy production required for steel production. The company was founded in 2021 and is headquartered in Vancouver, Canada.

TMC the metals company Inc

TMC is trending as investors react to the NOAA determination that the company's deep-seabed mining application is in full compliance, fueling community anticipation for accelerated permitting and long-term supply dominance. Investors are actively discussing the potential for a major deal with automotive manufacturers and tracking progress toward commercialization as a key catalyst for potential valuation re-rating.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

Sandisk Corp is seeing significant volatility as investors weigh a blockbuster earnings report and a massive share buyback against a "sell-the-news" reaction following a major year-to-date rally. While the community is actively debating the sustainability of the memory supercycle and debating whether current price levels represent an attractive entry point or an overextended bubble, sentiment remains sharply divided between bulls citing massive AI-driven demand and bears predicting a cyclical pullback.

Akanda Corp. is a cannabis cultivation, manufacturing, and distribution company, which engages in the provision of premium quality and ethically sourced medical cannabis products to patients. The company cultivates and processes natural cannabis at facilities in the Kingdom of Lesotho, Africa and intend to supply medicinal-grade cannabis biomass, cannabis flower, and cannabis concentrates to wholesalers. It also imports and sells medical cannabis-based products. The company was founded on July 16, 2021 and is headquartered in New Romney, the United Kingdom.

Akanda Corp

Akanda Corp is experiencing a violent short squeeze driven by its extremely low float and soaring borrow fees, with investors actively debating whether the momentum will sustain toward triple digits or collapse under the threat of future dilution. The community remains sharply divided, as bulls point to technical setup and forced short covering while bears continue to dismiss the stock as a low-revenue pump-and-dump scheme.

Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of immunotherapies to treat cancer and autoimmune diseases. Its products include CUE-400 series (autoimmune diseases), CUE-500 series (targeted cell depletion), and CUE-100 series (Oncology). The company was founded by Ronald D. Seidel III, Steven Almo, and Rodolfo Chaparro on December 31, 2014 and is headquartered in Boston, MA.

Cue Biopharma Inc

Cue Biopharma is trending due to a combination of clinical-stage momentum, a private placement financing announcement, and ongoing speculative chatter regarding a potential short squeeze. Investors are actively debating the company's long-term pivot toward autoimmune therapies and the impact of recent technical events, including a reverse stock split, on the stock's future liquidity and volatility.

Zeta Global Holdings Corp. operates as a marketing technology software company, which engages in the provision of enterprises with consumer intelligence and marketing automation software. It enables its customers to target, connect and engage consumers through software that delivers marketing across all addressable channels, including email, social media, web chat, connected TV and video among others. The company was founded by David A. Steinberg and John Sculley on May 9, 2012 and is headquartered in New York, NY.

Zeta Global Holdings Corp - Ordinary Shares - Class A

Zeta Global Holdings Corp

Zeta Global is currently generating significant investor interest following strong earnings performance and the launch of its Athena AI platform, which has led to community discussions surrounding its potential for a short squeeze and long-term scaling. While investors remain divided over high stock-based compensation and market volatility, bulls are actively accumulating shares and advocating for a hold strategy, citing the company's consistent revenue growth and expanding enterprise adoption as key catalysts for future appreciation.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian is facing intense scrutiny as shareholders debate the optics of a massive executive compensation package for CEO RJ Scaringe, even as the company works to ramp up R2 production. While the community remains divided over the firm's long-term path to profitability, investors are heavily focused on upcoming earnings and the potential for a significant shift in the stock's momentum.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apple is drawing intense trader attention as a strong earnings beat, a massive share buyback authorization, and a dividend hike fuel optimism despite a modest post-market reaction. The community is actively debating the company's long-term leadership transition and whether these results can sustain momentum toward the 300 level.

Roblox Corp. engages in the provision of online gaming services. Its platform consists of Roblox Client, Roblox Studio, and Roblox Cloud. Roblox Client is an application that allows users to explore 3D digital worlds. Roblox Studio is the toolset that allows developers and creators to build, publish, and operate 3D experiences and other content accessed with Roblox Client. Roblox Cloud includes the services and infrastructure that power the human co-experience platforms. The company was founded by Erik Cassel and David B. Baszucki in March 2004 and is headquartered in San Mateo, CA.

Roblox Corporation - Ordinary Shares - Class A

Roblox Corp.

Roblox Corp. shares are trending after a significant post-earnings selloff, driven by a lower-than-expected full-year bookings outlook and engagement headwinds from new safety and age-verification protocols. While community sentiment is deeply polarized between those viewing the price drop as an attractive entry point for a platform with strong long-term engagement and those concerned about regulatory risks and predatory behavior, traders remain focused on the potential for volatility as the stock tests key support levels.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is seeing significant momentum as investors digest major hyperscaler earnings and reports of an industry-wide memory supply deficit, fueling strong bullish sentiment regarding the sector's long-term growth. The community remains highly focused on the company's favorable valuation compared to peers and its pivotal role in the ongoing AI-driven memory super cycle.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The company launched Testosterone Rx+, a once-daily pill designed to help the body naturally increase testosterone levels.</li><li>The rollout follows a recent FDA order supporting expanded testosterone therapy use for men with low libido from idiopathic hypogonadism.</li><li>The testosterone push comes as the FDA proposes restricting compounding of GLP-1 ingredients such as Semaglutide and Tirzepatide.</li></ul>Shares of Hims &amp; Hers Health, Inc. (HIMS) snapped a three-day losing streak on Thursday after the telehealth firm expanded its testosterone-care offering, creating a new growth pillar as competition intensifies across the crowded GLP-1 weight-loss market.<a href="https://stocktwits.com/symbol/HIMS">HIMS stock</a> ended over 3% higher at $27.17 on Thursday, snapping three straight sessions of losses. Shares also logged their second consecutive month of gains, up 31% in April.&nbsp;<h2 class="st-heading-2">Hims Turns Up Its Testosterone Push</h2>The company on Thursday introduced Testosterone Rx+, a once-daily pill that naturally increases testosterone levels, as part of its broader push into men’s hormone therapies following a recent regulatory push supporting the use of testosterone therapy.Recently, the U.S. Food and Drug Administration (FDA) encouraged sponsors of approved testosterone replacement therapies to explore a potential new indication for treating low libido from idiopathic hypogonadism.Hims began building its testosterone platform in September 2025, allowing providers to prescribe Enclomiphene-based treatments that help the body produce more of its own testosterone, while preserving fertility. The company also introduced combination therapy with Tadalafil, a medication used to treat erectile dysfunction, for men with low testosterone.&nbsp;Testosterone Rx+ builds on the same approach by combining Enclomiphene with zinc, vitamins B6 and B12, and L-arginine, an amino acid for better blood flow, in a single pill. According to company data, 95% of customers saw increases in testosterone levels, with 80% reaching optimal levels within 60 days.The program also includes symptom-screening tools, at-home lab testing kits, and virtual care through the platform.<h2 class="st-heading-2">GLP-1 Crackdown Lifts Testosterone Bet</h2>The testosterone expansion comes as regulators tighten oversight around compounded obesity medicines that have previously benefited telehealth firms.The FDA recently proposed excluding key GLP-1 ingredients, such as Semaglutide and Tirzepatide, from its 503B bulk list, which determines when outsourcing facilities can compound medicines from raw ingredients. The proposal could limit the large-scale availability of compounded versions and increase reliance on branded therapies, underscoring the importance of additional revenue engines, such as testosterone care, within Hims’ portfolio.Earlier this year, Novo Nordisk filed a patent infringement lawsuit related to compounded semaglutide offerings before reaching an agreement with Hims to provide access to FDA-approved versions of Wegovy and Ozempic through the platform.<h2 class="st-heading-2">GLP-1 Rivals Crowd The Field</h2>Competition across the weight-loss treatment ecosystem continues to intensify as Novo Nordisk and Eli Lilly scale blockbuster GLP-1 therapies, while large tech players such as Amazon also enter the weight-loss space.&nbsp;Firms such as Structure Therapeutics are advancing an oral GLP-1 candidate that showed more than 16% weight loss in mid-stage trials, while Altimmune is progressing its Pemvidutide program toward Phase 3 development after aligning trial plans with the FDA.Meanwhile, upcoming FDA reviews of peptide substances for possible inclusion on the federal 503A bulks list could create another lifeline for Hims to expand peptide-based treatment offerings on its platform.<h2 class="st-heading-2">How Do Retail Traders Feel About HIMS?</h2>On Stocktwits, retail sentiment was ‘bearish’ amid ‘low’ message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/hims_ss_png_58e90e4540.webp" alt="hims ss.png" width="976" height="140"><figcaption>HIMS sentiment and message volume as of May 1 | Source: Stocktwits</figcaption></figure>One user&nbsp;<a href="https://stocktwits.com/Cole_DeFranco/message/651971960">said</a>, “Peptides are coming in July. See you at $70 in September!”<stembedurl>https://stocktwits.com/Cole_DeFranco/message/651971960</stembedurl>Another user&nbsp;<a href="https://stocktwits.com/wwmeinc/message/651934177">said</a>, Good to see the FDA helping the cause by making drug development a business that should be protected.”<stembedurl>https://stocktwits.com/wwmeinc/message/651934177</stembedurl>HIMS stock has declined 18% over the past year.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sls-stock-retail-no-vote-20m-share-plan-before-aml-results/cZQNDC3ReIp">SLS Stock Tests $5 Again: Retail Targets ‘No’ Vote On 20M Share Dilution Push Before AML Trial Results&nbsp;</a>

In this photo illustration, a person holds a smartphone displaying the logo of Hims & Hers Health Inc. (NYSE: HIMS). (Photo illustration by Cheng Xin/Getty Images)

HIMS Stock On The Mend? New Testosterone Push Builds As GLP-1 Gold Rush Gets Crowded 

Hims & Hers Health Inc - According to company data, 95% of users saw testosterone increases, with 80% reaching optimal levels within 60 days.

Equity

According to company data, 95% of users saw testosterone increases, with 80% reaching optimal levels within 60 days.

HIMS vs. TDOC: Which Digital Health Stock Offers Better Upside Now?

Hims & Hers and Teladoc Health are taking different paths in digital health, but which stock offers stronger upside now? Let's dive in.

<ul class="summary-bullets"><li>Semaglutide, the key ingredient in Novo Nordisk’s Wegovy and Ozempic, and Tirzepatide, sold by Eli Lilly as Zepbound and Mounjaro, would be excluded from bulk compounding.</li><li>The 503B Bulk List features drug ingredients considered medically necessary, allowing approved outsourcing facilities to use them to make compounded medicines.</li><li>The agency said there is insufficient evidence to justify broader access to compounded versions.</li></ul>The U.S. Food and Drug Administration, on Thursday, issued a proposal to exclude several popular weight-loss and diabetes drugs from its 503B bulks list, limiting how they can be compounded by outsourcing facilities.Semaglutide, the key ingredient in Novo Nordisk’s (NVO) Wegovy and Ozempic, and Tirzepatide, sold by Eli Lilly (LLY) as Zepbound and Mounjaro, would be excluded from bulk compounding. The Liraglutide.<h2 class="st-heading-2">FDA Sees No Clinical Need For Compounding Weight Loss Drugs</h2>The 503B Bulk List is an FDA-approved list of drug ingredients considered medically necessary, allowing approved outsourcing facilities to use them to make compounded medicines. In most cases, facilities can only compound drugs from bulk ingredients if they appear on this list or if the drug is officially in shortage.After reviewing available data, the FDA said it found no clear clinical need to allow compounding of these drugs from raw ingredients. The agency added that its decision is based on patient safety and medical necessity, noting that there is insufficient evidence to justify broader access to compounded versions.“When FDA-approved drugs are available, outsourcing facilities cannot lawfully compound using bulk drug substances unless there is a clear clinical need,” said FDA Commissioner Marty Makary.<h2 class="st-heading-2">FDA’s Concerns With Compounded Weight Loss Drugs</h2>The agency has been vocal about its issue with compounded weight-loss drugs. In February, the FDA said it intends to tighten rules around GLP-1 ingredients used in compounded medicines, citing concerns about quality, safety, and possible legal issues. Compounded drugs are not reviewed or approved by the FDA.The agency <a href="https://stocktwits.com/news-articles/markets/equity/hims-stock-plunges-after-hours-fda-chief-warns-of-swift-action-on-copycat-drugs-after-novo-semaglutide-knockoff-launch/cZbnUBER4nQ">added</a> that compounded GLP-1 drugs should be used only when a patient’s needs cannot be met by an approved treatment. It also flagged risks such as improper storage, dosing mistakes, and counterfeit or misleadingly marketed products.Earlier this year, Novo Nordisk sued Hims &amp; Hers (HIMS) for patent infringement after HIMS launched a $49-per-month compounded version of Wegovy, claiming it used the same active ingredient as the branded drug. However, the two companies later reconciled,<a href="https://stocktwits.com/news-articles/markets/equity/hims-platform-novo-wegovy-availability-stock-focus/cZ3sTJFRIkI">&nbsp;teaming</a> up to offer FDA-approved versions of Wegovy and Ozempic at more affordable self-pay prices on the telehealth platform.Meanwhile, shares of LLY and NVO gained 9% and 5%, respectively, while HIMS edged 0.5% lower and Teladoc Health (TDOC) fell 2%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/eli-lilly-lly-stock-up-earnings-mounjaro-zepbound/cZBMJq7Re4X">LLY Stock Up 7% Pre-Market As Mounjaro, Zepbound Sales Smash Expectations – Retail Bets On Run Toward $1,000</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

 In this photo illustration, the United States Food and Drug Administration (FDA) logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

FDA Moves To Block Compounded Versions Of Popular Weight-Loss Drugs – NVO, LLY Stocks Gain

The FDA issued a proposal to exclude several popular weight-loss and diabetes drugs from being compounded by outsourcing facilities.

Hims & Hers Health, Inc. (NYSE:HIMS) Given Consensus Rating of "Hold" by Analysts

Shares of Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) have been assigned an average recommendation of "Hold" from the eighteen brokerages that are currently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, thirteen have issued a...

Hims & Hers Expands Digital-First Access to Personalized Healthcare

HIMS broadens digital-first care with Novo Nordisk GLP-1 access, new cancer detection and Labs tools, along with expansion into Canada and Europe.

Hims & Hers Health, Inc. (HIMS) is a Top-Ranked Momentum Stock: Should You Buy?

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

<ul class="summary-bullets"><li>The package remained heavily equity-driven, with 306,406 RSUs and performance stock options tied to long-term results.</li><li>Hims met 94% of its revenue target and 98% of its adjusted EBITDA target last year.</li><li>The compensation vote comes as Hims deepens its presence in the high-stakes GLP-1 weight-loss market.</li></ul>Shares of Hims &amp; Hers Health, Inc. (HIMS) logged its worst day in a month on Tuesday after a fresh filing revealed that CEO Andrew Dudum earned about 272x the company’s median employee compensation, even amid heated competition in its core weight-loss business.<a href="https://stocktwits.com/symbol/HIMS">HIMS stock</a> declined over 5% on Tuesday to end at $27.91. Shares are still poised to mark their second straight month of gains after jumping 34% so far in April.&nbsp;<h2 class="st-heading-2">Hims CEO's Massive CEO-To-Worker Pay Gap</h2>The disclosure comes ahead of the company’s upcoming annual meeting on June 11, where shareholders will vote on executive pay. An interesting detail in the filing showed that Dudum earned a massive 272x the company’s median employee pay, with median pay reported at $84,402 compared with Dudum’s total compensation of $22.96 million last year. However, his total pay was down about 7% from the previous year.Despite the decline, the structure of the pay package remained heavily tilted towards long-term incentives rather than fixed cash compensation. The company confirmed that Dudum’s base salary was about the same as 2024 levels, and his target annual incentive are still set at 100% of base salary, consistent with the prior year.The filing also said that Dudum received $240,000 in security-related reimbursements as part of “all other compensation” last year.<h2 class="st-heading-2">Stock Awards Made Up The Real Pay</h2>Short-term incentives under the company’s compensation plan were mainly related to performance based on targets for revenue and adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA).Last year, the company met 94% of its revenue target and 98% of its adjusted EBITDA target, resulting in executives earning 93.72% of their target annual incentive bonus. Based on these performance levels, Dudum received an annual incentive payout of $585,763 for the year.Additionally, Dudum received 306,406 restricted stock units (RSUs), along with performance-based stock option awards that could increase in value depending on how Hims performs over time. Under the grant structure, the options convert into 278,622 shares at the minimum performance level, 557,244 shares at the target level, and up to 1.39 million shares if maximum performance conditions are met, with an exercise price of $34.71 per share.&nbsp;<h2 class="st-heading-2">Hims Fights For A Slice Of The GLP-1 Pie</h2>The compensation vote comes as Hims enters its next phase of growth in a heavily competitive weight-loss market, where both established healthcare players and emerging digital platforms are vying for a slice in the heated GLP-1 segment amid strong demand for newer obesity therapies.&nbsp;Recently, the company expanded access to branded treatments from Novo Nordisk and Eli Lilly, while also adjusting its strategy around compounded alternatives following regulatory scrutiny affecting the broader telehealth GLP-1 ecosystem.&nbsp;Meanwhile, competition in the GLP-1 space has extended well beyond pharma players, with Amazon expanding its presence in the category through its One Medical platform. Rival telehealth provider Ro has also introduced aggressive pricing changes across its subscription-based GLP-1 programs.<h2 class="st-heading-2">How Do Retail Traders Feel About HIMS?</h2>On Stocktwits, retail sentiment for HIMS was ‘neutral’ amid ‘normal’ message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/hims_ss_png_d12f222abf.webp" alt="hims ss.png" width="974" height="144"><figcaption>TSLA sentiment and message volume as of April 29 | Source: Stocktwits</figcaption></figure>One user&nbsp;<a href="https://stocktwits.com/ClarissaLove/message/651686208">noted</a> that, “Amazon’s One Medical App is on the verge of surpassing HIMS for the first time ever”<stembedurl>https://stocktwits.com/ClarissaLove/message/651686208</stembedurl>Meanwhile, a bullish user&nbsp;<a href="https://stocktwits.com/Coney/message/651669468">said</a>, “besides today, we went over $30 the previous 6 trading days.. With a little more volume we should get back there shortly”<stembedurl>https://stocktwits.com/Coney/message/651669468</stembedurl>HIMS stock has declined 2% over the past year.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/onds-stock-best-month-2026-battlefield-drone-pitch-us-operators/cZBqsJARe3B">ONDS Stock Eyes Best Month Of 2026: New Defense Unit Lines Up Battlefield Drone Pitch To US Operators&nbsp;</a>

HIMS Stock Loses Weight: CEO's Massive 272x Pay Gap With Workers Tips The Scales Ahead Of Shareholder Vote

A fresh filing revealed that CEO Andrew Dudum's total pay was $22.96 million in 2025, compared with the median employee pay of $84,402.

HIMS Stock Dips: CEO Pay Ratio Hits 272x Ahead Of Shareholder Vote

Healthcare Stocks To Watch Today - April 28th

UnitedHealth Group, Johnson & Johnson, Centene, Hims & Hers Health, and HCA Healthcare are the five Healthcare stocks to watch today, according to MarketBeat's stock screener tool. Healthcare stocks...

OMCL vs. HIMS: Which Stock Should Value Investors Buy Now?

OMCL vs. HIMS: Which Stock Is the Better Value Option?

BrightSpring Before Q1 Earnings: Buy, Sell or Hold the Stock Now?

BTSG heads into Q1 earnings with strong pharmacy and home-care momentum, but margin pressures, integration costs and slower growth may temper expectations.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Current Price	$27.37
Prev Close	$27.17
Open	$27.29
Dividend Yield	0.00%
50-Day Moving Average	$21.83
Beta	2.23
Avg. Volume	44.55M
PE Ratio	52.04

52-Week High	$70.43
52-Week Low	$13.74
Market Capitalization	$6.19B
EPS (Annual)	$0.5123
Price to Book	11.41
Revenue Per Employee	$961,358.31

HIMS
Hims & Hers Health Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest HIMS News

HIMSHims & Hers Health Inc